Latest News and Press Releases

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 29, 2023 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of...

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 27, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...

EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels:...

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special...

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...

Regulated Information – Inside Information Waives Key Conditions for Up to €3.5 Million in Atlas FundingReduces Cash Covenant and Total Debt for Kreos/Pontifax Loan Leuven, BELGIUM, Boston,...

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special...

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special...

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special...